Valneva hits 2024 sales target but plans lower cash burn in 2025
Product sales for the vaccine specialist Valneva reached 鈧�170m despite slow US sales of its chikungunya vaccine.
Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens
Bispecific antibody startup Bambusa raises $90m to fund clinical trials
EU reshapes HTAs: is the industry ready for it?
Innate鈥檚 lacutamab gains FDA breakthrough therapy designation
GSK鈥檚 Penmenvy meningococcal vaccine gains FDA approval
网曝门
View More
Themes
View MoreUK awards 拢82.6m to AI drug discovery companies
The UK announced the funding at the AI Action Summit in Paris where it abstained from signing a declaration on an inclusive approach to AI.
More themes
Data Insights
View MoreCell & gene therapy: the leading companies in recombinant AAV gene therapy revealed
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
GlobalData Reports
View MoreDigital Magazine
View MorePharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
The AI advantage in discovering new medicines聽
AI鈥檚 potential in women鈥檚 health exciting, says Gates Foundation leader
Shionogi awarded $375m from HHS for preventative Covid-19 injectable
Pfizer believes in the metaverse: will healthcare thaw the technology’s winter?